Risk reduction was similar with respect to MSI status in a larger study from 2020 (6), but risk reduction with the predominantly proximal CRC subtypes (MSI-high, BRAF mutation, CIMP-high, sessile serrated pathway CRC) was only observed in the age group older than 71 years. This evidence concerns the gene BRAF and colorectal carcinoma.